Advertisement
Advertisement

BDX

BDX logo

Becton Dickinson & Co.

227.81
USD
+3.98
+1.78%
Dec 20, 15:59 UTC -5
Closed
...

Becton Dickinson & Co. Profile

About

Becton, Dickinson and Company, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. BD's operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. The company's organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional. BD Medical: BD Medical's major product lines include needles, syringes and intravenous catheters for medication delivery and generic prefilled injectables. BD Life Sciences - BD Diagnostics provides products for the safe collection and transport of diagnostics specimens to detect a broad range of infectious diseases, healthcare-associated infections and cancer. BD Biosciences produces research and clinical tools that facilitate the study of cells to gain a better understanding of normal and disease processes. With the acquisition of C.R. Bard, BD added a new segment - BD Interventional.

Info & Links

CEO

Thomas E. Polen

Headquarters

ONE BECTON DRIVE
FRANKLIN LAKES, NJ 07417, UNITED STATES

Website

www.bd.com

Auditor

Ernst & Young LLP

Share holders

10,012

Employees

74,000

Becton Dickinson & Co. Statistics

Valuation Measures

Market Capitalization2

65.86B

Enterprise Value

84.12B

Enterprise Value/EBITDA(ttm)

17.96

Price to Earnings Ratio(ttm)

17.01

Price to Sales(ttm)

3.21

Price to Book(mrq)

2.50

Price to Cash(ytd)

10.59

Profitability

Gross Margin(ttm)

45.18%

Operating Margin(ttm)

18.95%

Profit Margin(ttm)

8.43%

Return on Equity(ttm)

14.89%

Return on Invested Capital(ttm)

4.02%

Return on Assets(ttm)

6.98%

Income Statement

Revenue(ttm)

20.18B

Revenue Per Share(ttm)

69.79

Gross Profit(ttm)

9.13B

EBITDA(ttm)3

4.68B

Net Income Available to Common(ttm)

1.71B

Diluted EPS(ttm)

5.94

Share Statistics

Beta (5Y Monthly)

0.41

52-Week Change

-2.55%

S&P 500 52-Week Change

24.74%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

289.12M

Dividend Yield

1.86%

Float4

288.23M

% Held by Insiders

0.31%

% Held by Institutions

86.97%

Balance Sheet

Total Cash(mrq)

2.30B

Total Cash Per Share(mrq)

7.96

Total Debt(mrq)

20.11B

Total Debt/Equity(mrq)

77.67%

Current Ratio(mrq)

1.17%

Quick Ratio(mrq)

0.74%

Book Value Per Share(mrq)

89.55

Cash Flow

Operating Cash Flow Per Share(ytd)

13.21

Free Cash Flow(ytd)

3.12B

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement